Congress Materials – American Society of Clinical Oncology (AM 2025)
2025 American Society of Clinical Oncology | May 30-Jun 3 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib: Outcomes by Osimertinib Resistance Mechanisms in MARIPOSA-2
Raffaele Califano, Antonio Passaro, Jiunn-Liang Tan, Ana Blasco, Juan Li, Clarissa Baldotto, Maria Del Rosario Garcia Campelo, Richu Sharma, Karen L. Reckamp, Sandeep H. Mashru, Toshiaki Takahashi, Pei-Ling Chu, Sandeep Kumar, Sujay Shah, Xuerui Luo, Jiarui Zhang, Joshua C. Curtin, Alexis B. Cortot
This document will be available on May 31 2025
Amivantamab Treatment and Intra-Tumoral Gene Expression and Immune Cell Changes in Refractory Metastatic Colorectal Cancer (mCRC): Whole Transcriptome RNA-Sequencing Analysis From the OrigAMI-1 Study
Cathy Eng, Paul E Oberstein, J Randolph Hecht, Filippo Pietrantonio, Dirk Arnold, Yong Sang Hong, Myung Ah Lee, Harvey Yu-Li Su, Sae-Won Han, Rianka Bhattacharya, Emrullah Yilmaz, Mahesh Daksh, Mahadi Baig, Sanjib Chowdhury, Xuesong Lyu, Joshua C Curtin, Medha Kamat, Michael Gormley, Bharvin Patel, Elena Élez
This document will be available on May 31 2025
Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): CARTITUDE-4 Survival Subgroup Analyses
Surbhi Sidana, Joaquín Martínez-López, Abdullah M. Khan, Albert Oriol, Andrew Spencer, Binod Dhakal, Yaël C. Cohen, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús San-Miguel, Salomon Manier, Diana Chen, Katherine Li, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Simon J. Harrison
This document will be available on June 1 2025
Daratumumab + Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible/ Transplant-Deferred Newly Diagnosed Multiple Myeloma: Phase 3 CEPHEUS Trial Cytogenetic Subgroup Analysis
Nizar J. Bahlis, Saad Z. Usmani, Thierry Facon, Sonja Zweegman, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Angelo Maiolino, Mai Ngo, Maria Krevvata, Melissa Rowe, Vania Hungria
This document will be available on June 1 2025
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study
Thierry Facon, Sonja Zweegman, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc J. Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Meral Beksac, Angelo Maiolino, Jianping Wang, Melissa Rowe, Robin L. Carson, Saad Z. Usmani
This document will be available on June 2 2025
Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial
Jill Feldman, Byoung Chul Cho, Weimin Li, Nicolas Girard, Milena Mak, Maxwell B. Sauder, Farastuk Bozorgmehr, Jiunn Liang Tan, Jin-Yuan Shih, Danny Nguyen, Enriqueta Felip, Julia Schuchard, Tonatiuh Romero, Yichuan Xia, Joshua M. Bauml, Jairo A. Simões, Parthiv J. Mahadevia, Mark Wildgust, Alexander I. Spira
This document will be available on May 31 2025
Efficacy and Safety From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Analyses at an Extended Median Follow-up
Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, María-Victoria Mateos, Jing Christine Ye, Chalmer Tomlinson, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara J. Masterson, Veronique Vreys, Bonnie W Lau, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Ajai Chari
This document will be available on June 1 2025
Efficacy and Safety of First-Line Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma Who Were Older or Had TP53 Mutations in the SYMPATICO Study
Michael Wang, Marc S. Hoffmann, Tomasz Wrobel, Marek Trneny, David Belada, Fatih Demirkan, Panayiotis Panayiotidis, Wojciech Jurczak, Pier L. Zinzani, Mary-Margaret Keating, Sung-Soo Yoon, Miklós Egyed, Constantine S. Tam, Nathalie Johnson, Edith Szafer-Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Gottfried von Keudell
This document will be available on May 31 2025
Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
Paolo Ghia, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O’Brien, Ryan Jacobs, Xavier C. Badoux, Livio Trentin, Masa Lasica, Dennis Carney, Anna Elinder Camburn, Javier De la Serna, Edith Szafer-Glusman, Cathy Zhou, Jutta K. Neuenburg, James P. Dean, William G. Wierda, Constantine S. Tam
This document will be available on June 1 2025
First-In-Human Study of JNJ-79635322 (JNJ-5322), a Novel, Next-Generation Trispecific Antibody (TsAb), in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Initial Phase 1 Results
Niels W.C.J. van de Donk, Gala Vega, Aurore Perrot, Sebastian Anguille, Albert Oriol, Monique Minnema, Martin F. Kaiser, Hans C. Lee, Alfred Garfall, Jeffrey V. Matous, Larysa J. Sanchez, Azra Borogovac, Lionel Karlin, Saad Z. Usmani, Joseph Weidman, Sangmin Lee, Maria-Victoria Mateos, Paula Rodriguez-Otero, Cyrille Touzeau, Rakesh Popat
This document will be available on June 3 2025
Impact of somatic/germline homologous recombination repair (HRR) alterations on metastatic hormone-sensitive prostate cancer (mHSPC) outcomes by disease volume
David Olmos, David Lorente, Ana Jambrina, Daniel Tello Velasco, Ignacio Gonzalez-Ginel, Nuria Romero-Laorden, Diogo Nunes-Carneiro, María Ovejero Sánchez, Jordi Miguel, Fernando Alberca del Arco, Daniel Pérez-Argüelles, Alexandra Jürgens, Camille Capone, Marco Trevisan, Suzy Van Sanden, Gabriel Stulnig, Alfredo Rodriguez Antolin, Daniel E. Castellano, Bernardo Herrera-Imbroda, Elena Castro
This document will be available on June 2 2025
Inferring FGFR Status From H&E Images Using Digital Pathology to Identify Patients for Early-Stage Bladder Cancer Targeted Therapies
Albert Juan Ramon, Fatemeh Koochaki, Chaitanya Parmar, Patricia Raciti, Neil Beeharry, Christopher J. Medberry, Cheng Zhang, David Weingeist, Nicole Stone, Spyros Triantos, Joel Greshock, Kristopher A. Standish
This document will be available on June 2 2025
Long-Term (≥5 year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Peter Voorhees, Sundar Jagannath, Tom G. Martin, Yi Lin, Adam D. Cohen, Noopur S. Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus G. Berdeja, Binod Dhakal, Andrzej J. Jakubowiak, Samir S. Parekh, Hui Li, Rocio Montes de Oca, Huabin Sun, Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel
This document will be available on June 3 2025
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer
Dirk Arnold, Andres Cervantes, Michel Ducreux, Sae-Won Han, Heinz-Josef Lenz, Kei Muro, Kanwal Raghav, Lin Shen, Jaw Yuan Wang, Pei Jye Voon, Hung-Chih Hsu, Bing Xia, Ryota Iwasawa, Shamita Carrigan, Brooke Diorio, Patricia Lorenzini, Sandip Acharya, Seema Sethi, Mahadi Baig, Filippo Pietrantonio
This document will be available on May 31 2025
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer
J Randolph Hecht, Elena Élez, Cathy Eng, Peter Gibbs, Jenny Seligmann, Ruihua Xu, Kensei Yamaguchi, Jaw Yuan Wang, Hao Wei Teng, Leonardo Trani, Honeylet Wortman-Vayn, Zhengyu Jiang, Brooke Diorio, Patricia Lorenzini, Christine Baudelet, Seema Sethi, Mahadi Baig, Chiara Cremolini
This document will be available on May 31 2025
Phase 1 Study Results of JNJ-78278343 (Pasritamig) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Capucine Baldini, Armelle Vinceneux, Debbie G. Robbrecht, Bernard D. Doger De Spéville, Karen A. Autio, Michael T. Schweizer, Emiliano Calvo, Laura Medina Rodriguez, Marloes V. Dongen, Jean-Laurent Deville, Alice Bernard-Tessier, Debopriya Ghosh, Kristin M. Shotts, Pharavee Jaiprasart, Leanne Cartee, Daria Gaut, Josh D. Lauring, Sherry C. Wang, Victor M. Villalobos, Mark N. Stein
This document will be available on June 1 2025
Phase 3 AMPLITUDE Trial: Niraparib (NIRA) and Abiraterone Acetate Plus Prednisone (AAP) for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Patients (Pts) With Alterations in Homologous Recombination Repair (HRR) Genes
Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstatiou, Mustafa Özgüroğlu, Andrea J. Pereira de Santana Gomes, Karina C. Vianna, Hong Luo, Heather H. Cheng, Won Kim, Carly R. Varela, Daneen Schaeffer, Shiva Dibaj, Susan Li, Fei Shen, Suneel Dinkar Mundle, David Olmos, Kim N. Chi, Dana E. Rathkopf, on behalf of the AMPLITUDE investigators
This document will be available on June 3 2025
Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Update on the Open-Label, Phase 2, Randomized TALISMAN Study
Rakesh Popat, Alexa Laheij, Niels W.C.J. van de Donk, Richard L Doty, Jim Omel, Brea Lipe, Leo Rasche, Ajai Chari, Kelly Kato, Shaozhou Tian Ken, Deeksha Vishwamitra, Jacqueline Speier, Jennifer Schultz, Kasey Bolyard, Kathleen S. Gray, Gloria Aguilar, Mariana Fernandez, Keqin Qi, Larysa Sanchez
This document will be available on June 1 2025
Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease MRD Negativity in the Phase 3 PERSEUS Trial
Philippe Moreau, Pieter Sonneveld, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier P. Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Huiling Pei, Anna Sitthi-Amorn, Robin L. Carson, Meletios A. Dimopoulos, Paula Rodriguez-Otero, Mario Boccadoro
This document will be available on June 3 2025
Subsequent Treatments and Outcomes in Bacillus Calmette-Guerin Unresponsive Patients with High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ: A Real-World Data Analysis
Ariel Bourla, Ran Sun, Shalaka Hampras, Bolan Linghu, Jose Zamalloa, Emily Scherer, Wendy Crist, Sabine Brookman-May, Joel Greshock, Jessica Chung, Hussein Sweiti
This document will be available on June 2 2025
Copies of these presentation are for personal use only and may not be reproduced without permission from ASCO® or the author of this presentation.